Last $13.43 USD
Change Today +0.69 / 5.44%
Volume 53.1K
STML On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:07 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

stemline therapeutics inc (STML) Snapshot

Open
$13.25
Previous Close
$12.74
Day High
$13.70
Day Low
$13.04
52 Week High
10/21/13 - $36.14
52 Week Low
09/5/14 - $10.50
Market Cap
178.1M
Average Volume 10 Days
114.0K
EPS TTM
$-2.22
Shares Outstanding
13.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMLINE THERAPEUTICS INC (STML)

Related News

No related news articles were found.

stemline therapeutics inc (STML) Related Businessweek News

No Related Businessweek News Found

stemline therapeutics inc (STML) Details

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. It develops SL-401, a clinically active targeted therapy directed to the interleukin-3 receptor, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, a clinically active therapeutic cancer vaccine that has completed two Phase I/II clinical trials. The company was founded in 2003 and is headquartered in New York, New York.

20 Employees
Last Reported Date: 08/14/14
Founded in 2003

stemline therapeutics inc (STML) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $770.9K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: --
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $552.1K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $516.7K
Compensation as of Fiscal Year 2013.

stemline therapeutics inc (STML) Key Developments

Stemline Therapeutics, Inc. Initiates SL-401 Trial in AML Patients in First Complete Response with Minimal Residual Disease

Stemline Therapeutics, Inc. announced the initiation of its second clinical trial for SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of a wide range of hematologic cancers. This trial will enroll patients with acute myeloid leukemia (AML) who have achieved a complete response (CR) following their first course of induction chemotherapy, but display evidence of minimal residual disease (MRD) in their bone marrow and are at high risk for relapse. The study is designed to enroll at least 33 patients and will include a brief lead-in that will transition into a larger expansion stage. The trial will evaluate, among other parameters, SL-401's ability to eradicate evidence of MRD and increase CR duration. Participating sites include MD Anderson Cancer Center (Houston, TX), Duke University Medical Center (Durham, NC), and other major centers. This trial follows the first trial of SL-401, which is in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory AML and is actively accruing patients. SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (IL-3R), a target present on tumor bulk and cancer stem cells (CSCs) of multiple hematologic cancer indications. SL-401 has demonstrated clinical activity in several indications, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), as well as preclinical activity in rare myeloproliferative disorders, multiple myeloma (MM), chronic myeloid leukemia (CML), and certain lymphoid leukemias and lymphomas.

Stemline Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 11:25 AM

Stemline Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 11:25 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Ivan Bergstein, Founder, Chairman, Chief Executive Officer and President.

Stemline Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Stemline Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported grant revenue of $71,429. Loss from operations was $6,046,026 compared to $5,155,947 a year ago. Net loss attributable to common stockholders was $6,012,698 or $0.47 per basic and diluted share compared to $5,450,638 or $0.55 per basic and diluted share a year ago. For the six months period, the company reported grant revenue of $142,429. Loss from operations was $15,080,242 compared to $10,485,140 a year ago. Net loss attributable to common stockholders was $15,012,625 or $1.16 per basic and diluted share compared to $10,956,284 or $1.37 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STML:US $13.43 USD +0.69

STML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for STML.
View Industry Companies
 

Industry Analysis

STML

Industry Average

Valuation STML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 785.9x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 701.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMLINE THERAPEUTICS INC, please visit www.stemline.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.